These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 31513929)
21. [Design, synthesis and activity evaluation of novel matrix metalloproteinases inhibitors based on the structure of enzyme]. Jia H; Guo YS; Ge YY; Wen H; Yang J; Yang XY; Du GH; Yang GZ Yao Xue Xue Bao; 2007 Dec; 42(12):1271-81. PubMed ID: 18338640 [TBL] [Abstract][Full Text] [Related]
22. Novel Matrix Metalloproteinase-9 (MMP-9) Inhibitors in Cancer Treatment. Rashid ZA; Bardaweel SK Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569509 [TBL] [Abstract][Full Text] [Related]
23. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket. Huang A; Joseph-McCarthy D; Lovering F; Sun L; Wang W; Xu W; Zhu Y; Cui J; Zhang Y; Levin JI Bioorg Med Chem; 2007 Sep; 15(18):6170-81. PubMed ID: 17606376 [TBL] [Abstract][Full Text] [Related]
24. Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors. Tauro M; Laghezza A; Loiodice F; Agamennone M; Campestre C; Tortorella P Bioorg Med Chem; 2013 Nov; 21(21):6456-65. PubMed ID: 24071448 [TBL] [Abstract][Full Text] [Related]
25. Matrix metalloproteinase inhibition by heterotrimeric triple-helical Peptide transition state analogues. Bhowmick M; Stawikowska R; Tokmina-Roszyk D; Fields GB Chembiochem; 2015 May; 16(7):1084-92. PubMed ID: 25766890 [TBL] [Abstract][Full Text] [Related]
26. The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma. Fields GB Cells; 2019 Aug; 8(9):. PubMed ID: 31461880 [TBL] [Abstract][Full Text] [Related]
27. Design and Structural Evolution of Matrix Metalloproteinase Inhibitors. Fischer T; Senn N; Riedl R Chemistry; 2019 Jun; 25(34):7960-7980. PubMed ID: 30720221 [TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors. Nara H; Sato K; Kaieda A; Oki H; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M Bioorg Med Chem; 2016 Dec; 24(23):6149-6165. PubMed ID: 27825552 [TBL] [Abstract][Full Text] [Related]
29. Structural basis for the highly selective inhibition of MMP-13. Engel CK; Pirard B; Schimanski S; Kirsch R; Habermann J; Klingler O; Schlotte V; Weithmann KU; Wendt KU Chem Biol; 2005 Feb; 12(2):181-9. PubMed ID: 15734645 [TBL] [Abstract][Full Text] [Related]
30. Natural products as a gold mine for selective matrix metalloproteinases inhibitors. Wang L; Li X; Zhang S; Lu W; Liao S; Liu X; Shan L; Shen X; Jiang H; Zhang W; Huang J; Li H Bioorg Med Chem; 2012 Jul; 20(13):4164-71. PubMed ID: 22658537 [TBL] [Abstract][Full Text] [Related]
31. Identification of Broad-Spectrum MMP Inhibitors by Virtual Screening. Gimeno A; Cuffaro D; Nuti E; Ojeda-Montes MJ; Beltrán-Debón R; Mulero M; Rossello A; Pujadas G; Garcia-Vallvé S Molecules; 2021 Jul; 26(15):. PubMed ID: 34361703 [TBL] [Abstract][Full Text] [Related]
32. Virtual Screening on MMP-13 Led to Discovering New Inhibitors Including a Non-Zinc Binding and a Micro Molar One: A Successful Example of Receptor Selection According to Cross-Docking Results for a Flexible Enzyme. Ramezani M; Shamsara J Comb Chem High Throughput Screen; 2017; 20(8):719-725. PubMed ID: 28814230 [TBL] [Abstract][Full Text] [Related]
33. Mechanisms of Action of Novel Drugs Targeting Angiogenesis-Promoting Matrix Metalloproteinases. Fields GB Front Immunol; 2019; 10():1278. PubMed ID: 31214203 [TBL] [Abstract][Full Text] [Related]
34. Molecular insights in repurposing selective COX-2 inhibitor celecoxib against matrix metalloproteinases in potentiating delayed wound healing: a molecular docking and MMPB/SA based analysis of molecular dynamic simulations. Mude L; Jupudi S; Swaroop AK; Tallapaneni V; Karri VVSR J Biomol Struct Dyn; 2024 Mar; 42(5):2437-2448. PubMed ID: 37160705 [TBL] [Abstract][Full Text] [Related]
35. Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach. Nara H; Sato K; Naito T; Mototani H; Oki H; Yamamoto Y; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M J Med Chem; 2014 Nov; 57(21):8886-902. PubMed ID: 25264600 [TBL] [Abstract][Full Text] [Related]
36. Identification of highly potent and selective MMP2 inhibitors addressing the S1' subsite with d-proline-based compounds. Lenci E; Innocenti R; Di Francescantonio T; Menchi G; Bianchini F; Contini A; Trabocchi A Bioorg Med Chem; 2019 May; 27(9):1891-1902. PubMed ID: 30926311 [TBL] [Abstract][Full Text] [Related]
37. Structural basis for matrix metalloproteinase-2 (MMP-2)-selective inhibitory action of β-amyloid precursor protein-derived inhibitor. Hashimoto H; Takeuchi T; Komatsu K; Miyazaki K; Sato M; Higashi S J Biol Chem; 2011 Sep; 286(38):33236-43. PubMed ID: 21813640 [TBL] [Abstract][Full Text] [Related]
38. Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors. Kiyama R; Tamura Y; Watanabe F; Tsuzuki H; Ohtani M; Yodo M J Med Chem; 1999 May; 42(10):1723-38. PubMed ID: 10346925 [TBL] [Abstract][Full Text] [Related]
39. Recent Research Advances in Selective Matrix Metalloproteinase-13 Inhibitors as Anti-Osteoarthritis Agents. Xie XW; Wan RZ; Liu ZP ChemMedChem; 2017 Aug; 12(15):1157-1168. PubMed ID: 28722301 [TBL] [Abstract][Full Text] [Related]